

Dated [●] 2020

**[NAME OF THE SELF-FINANCING PARTICIPANT]**

and

**GAVI ALLIANCE**

**COMMITMENT AGREEMENT**

**(COMMITTED PURCHASE ARRANGEMENT)**

This Commitment Agreement dated [●] 2020 and is made between:

- (1) [●] (the “**Participant**”); and
- (2) **THE GAVI ALLIANCE**, a non-profit foundation registered in the canton of Geneva (registry number CH-660-1699006-1) with offices at 2, Chemin des Mines, Geneva, Switzerland (“**Gavi**”).

**Whereas:**

- (A) The COVID-19 pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. Developing and deploying a safe and effective COVID-19 vaccine is essential to restoring normal economic activity.
- (B) Pooling demand with other countries through a joint mechanism vastly increases the probability of success for each country and global success in stamping out a disease which does not recognise borders.
- (C) Through the COVID-19 Vaccines Global Access facility (the “**COVAX Facility**”), countries have the opportunity to benefit from a portfolio of vaccine candidates using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand with greater scope than governments or regional groups can support on their own, giving their populations early access to safe and efficacious vaccines.
- (D) The COVAX Advance Market Commitment (the “**COVAX AMC**”) has been established to raise funding to enable Gavi to subsidise vaccine dose purchase through the COVAX Facility for 92 eligible economies through Official Development Assistance funding from donors, as well as through support from private foundations. The COVAX AMC helps ensure that all economies can participate in the COVAX Facility and access vaccines through it.
- (E) Gavi and/or a procurement agency acting on its behalf, will enter into advance purchase commitments with manufacturers for supply of vaccines for the benefit of the Participants. The COVAX Facility aims to procure 2 billion doses of a safe and efficacious vaccine by the end of 2021.
- (F) By participating in the COVAX Facility, the Participants will have access to doses of vaccine candidates as a result of the advance purchase commitments that Gavi will conclude with vaccine manufacturers. As doses from successful candidates become available, they will be allocated to all Participants in accordance with the Terms and Conditions (as defined below). The achievement of this will be subject to the availability of funding, from Participants as well as funding for the COVAX AMC. The total amount allocated to each Participant and COVAX AMC Eligible Economies (as defined below) over time may be more or less than 20%, depending on the funding that is made available as the provision of doses from the two financing streams (funding from Participants and the COVAX AMC) are separate. Lack of funding or readiness by a participant or set of participants would not delay the distribution of vaccines to other Participants in alignment with the Allocation Framework.
- (G) This Commitment Agreement is entered into by a Participant subscribing to the Committed Purchase Arrangement (as defined below).

IT IS THEREFORE AGREED as follows:

1. **DEFINITIONS AND INTERPRETATION**

1.1 **Definitions**

In this Agreement:

- (a) All terms capitalised but not otherwise defined shall have the meanings given to them in the Terms and Conditions attached to this Agreement at Schedule 1 (*Terms and Conditions*); and
- (b) The following terms shall have the following meanings:

**“Actual Procurement Price”** means the actual procurement price per dose of an Approved Vaccine at the time of purchase thereof from the Specified Manufacturer (as notified by the Specified Manufacturer to Gavi prior to the procurement of an Approved Vaccine by the Participant, which notification shall constitute conclusive evidence of the Actual Procurement Price);

**“Additional Payment Date”** has the meaning given to that term in Clause 2.2.

**“Additional Payment Percentage”** means the aggregate Additional Payments (if any) divided by the Committed Amount, multiplied by 100 (expressed as a percentage).

**“Additional Payments”** means payments by the Participant to Gavi at Gavi's request but at the Participant's sole discretion, in excess of the Down Payment, and in advance of procurement of an Approved Vaccine.

**“Adjusted Cost Per Dose”** means the cost in USD per dose of an Approved Vaccine, as determined in accordance with the Terms and Conditions by Gavi, and taking into account the following adjustments (if any) to the All-Inclusive Weighted Average Estimated Cost Per Dose:

- (i) the Actual Procurement Price;
- (ii) the actual access/speed premium, and financing/risk mitigation and operating costs; and
- (iii) deduction of the Participant Down Payment Discount, and the Participant Additional Payment Discount (if any).

**“All-Inclusive Weighted Average Estimated Cost Per Dose”** means US\$10.55.

**“Approved Vaccine”** means a vaccine against COVID-19 in respect of which Gavi has entered into an Advanced Purchase Commitment and which has WHO Prequalification or on an exceptional basis, at a minimum, licensure/authorisation in place from an SRA.

**“Authorisation”** means an authorisation, consent, approval, resolution, licence, exemption, filing, notarisation or registration.

**“Business Day”** means a day on which commercial banks are open for the transaction of general business (including dealings in foreign exchange) in Geneva, Switzerland and the capital city of the Participant.

**“Committed Amount”** means US\$[●]<sup>1</sup>.

**“Commitment Satisfaction Certificate”** has the meaning given to that term in Clause 4.1(d).

**“COVAX Facility Account”** means the account held in Gavi’s name with the following details:

<b>Account Name</b>	GAVI Alliance
<b>Account Number</b>	0240 264568.50U
<b>IBAN USD Account</b>	CH05 0024 0240 2645 6850 U
<b>Reference</b>	COVAX
<b>SWIFT</b>	UBSWCHZH80A
<b>Bank Details</b>	UBS Switzerland AG Rue des Noirettes 35 1227 Carouge

or such other account as Gavi may from time to time notify to the Participant in writing to no later than 10 Business Days prior to the relevant payment date).

**“Down Payment”** means US\$[●]<sup>2</sup>.

**“Financial Guarantee Amount”** means US\$[●]<sup>3</sup>.

**“Financial Guarantee Deadline”** means the date that is 21 days from the date of this Agreement.

**“Financing Condition”** has the meaning given to such term in Clause 5.

**“Gavi Transferee”** has the meaning given to such term in Clause 6.1.

**“Maximum Adjusted Cost Per Dose”** means US\$21.10.]

**“Participant Additional Payment Discount”** means an amount in USD that is equal to the Additional Payment Percentage of the All-Inclusive Weighted Average Estimated Cost Per Dose.

**“Participant Doses”** means doses of Approved Vaccine, up to a maximum of the Total Participant Doses, which Gavi has allocated to the Participant from time to time (as notified to the Participant in accordance with Clause 4.1(a)).

**“Participant Down Payment Discount”** means US\$1.60.

**“Participant Payment Deadline”** means 9 October 2020.

**“Procurement Period”** has the meaning given to such term in Clause 4.1(b).

**“Remaining Participant Doses”** means the Participant Doses minus any doses of Approved Vaccine that the Participant has already purchased from the Specified Manufacturer in the Procurement Period (which shall be determined on the basis of Commitment Satisfaction

---

<sup>1</sup> Note: To be an amount equal to the product of the All-Inclusive Weighted Average Estimated Cost Per Dose and the Total Participant Doses.

<sup>2</sup> Note: To be an amount equal to the product of US\$1.60 and the Total Participant Doses.

<sup>3</sup> Note: To be an amount equal to the Committed Amount less the Down Payment.

Certificates received by Gavi).

**“Specified Manufacturer”** means the manufacturer, or manufacturers, allocated to the Participant to supply Approved Vaccine, such allocation being determined in accordance with the Terms and Conditions.

**“Tax”** means all forms of taxation in the Participant’s country whether direct or indirect and whether levied by reference to income, profits, gains, net wealth, asset values, turnover, added value or other matters and statutory, governmental, state, provincial, local governmental or municipal impositions, duties, contributions, rates and levies (including social security contributions and any other payroll taxes), whenever and wherever imposed (whether imposed by way of a withholding or deduction for or on account of tax or otherwise) and in respect of any person and all penalties, charges, costs and interest relating thereto.

**“Terms and Conditions”** means the terms and conditions of the COVAX Facility as set out in Schedule 1 to this Agreement.

**“Total Participant Doses”** means [●]<sup>4</sup> number of doses of Approved Vaccine, sufficient to vaccinate [●]% of the Participant’s Population.

**“USD”** or **“US\$”** means the lawful currency of the United States of America.

**“VAT”** means

- (i) any tax imposed in compliance with the Council Directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112); and
- (ii) any other tax of a similar nature, whether imposed in a member state of the European Union in substitution for, or levied in addition to, such tax referred to in paragraph (i) above or imposed elsewhere.

## 1.2 Construction

Unless a contrary indication appears, any reference in this Agreement to:

- (i) **“assets”** includes present and future properties, revenues and rights of every description;
- (ii) **“this Agreement”** or any other agreement or instrument is a reference to that document or other agreement or instrument as amended or novated;
- (iii) a **“person”** includes any person, firm, company, corporation, government, state or agency of a state or any association, trust or partnership (whether or not having separate legal personality) or two or more of the foregoing;
- (iv) a **“regulation”** includes any regulation, rule, official directive, request or guideline (whether or not having the force of law) of any governmental, intergovernmental or supranational body, agency, department or regulatory, self-regulatory or other authority or organisation;

---

<sup>4</sup> Note: To be updated to reflect the actual number of doses. As set out in the Terms and Conditions, Participants may commit to purchase doses to cover between 10% and 50% of their Population through the COVAX Facility.

- (v) a provision of law is a reference to that provision as amended or re-enacted; and
- (vi) a time of day is a reference to London time.

### 1.3 **Singular, plural, gender**

References to one gender include all genders and references to the singular include the plural and vice versa.

### 1.4 **Clauses**

In this Agreement any reference to a “Clause” or a “Schedule” is, unless the context otherwise requires, a reference to a Clause of or a Schedule to this Agreement.

### 1.5 **Non-limiting effect of words**

The words “including”, “include”, “in particular” and words of similar effect shall not be deemed to limit the general effect of the words that precede them.

### 1.6 **Precedence**

If there is any conflict, apparent conflict or ambiguity in or between any of the sections of the Agreement set out below, the sections shall be applied in the following order of precedence:

- (i) the Clauses; then
- (ii) the Schedules, including the Terms and Conditions; then
- (iii) any other document referred to in this Agreement.

## 2. **COMMITMENT TO PAY AND PROCURE**

### 2.1 **Committed Amount**

The Participant, irrevocably and[, subject only to the satisfaction of the Financing Condition,]<sup>5</sup> unconditionally, undertakes to:

- (i) pay to Gavi the Down Payment before or on the Participant Payment Deadline; and
- (ii) subject to being allocated Approved Vaccine in accordance with the Terms and Conditions during the Procurement Period, pay to Gavi, a procurement agent and/or the Specified Manufacturer the Adjusted Cost Per Dose (as determined by Gavi in its sole discretion and notified in writing to the Participant together with the deadline for such payment(s) from time to time, which notification(s) shall be binding on the Participant and constituting conclusive evidence of the payments to be made by the Participant). Such amount, if paid from the Participant to Gavi, will be paid by Gavi to the Specified Manufacturer in discharge of: (a) Gavi’s obligations under the relevant Advance Purchase Commitment; or (b) the Participant’s obligations to pay the Actual Procurement Price to the Specified Manufacturer, as the case may be, and in each case after deduction by Gavi of an amount equal to its costs and expenses incurred which have not been covered in full by the Down Payment (and to the extent applicable, any Additional Payments),

provided that the undertakings in paragraph (i) and (ii) of Clause 2.1 above shall not at any time,

---

<sup>5</sup> Note: to be deleted for those Participants to whom the Financing Condition does not apply.

in aggregate, exceed the Committed Amount.

## 2.2 **Additional Payments**

In the event that, following a written request from Gavi, the Participant (acting in its sole discretion) elects to make any Additional Payments, the Participant undertakes that it will pay any such Additional Payments to Gavi on a date specified by Gavi in writing (the “**Additional Payment Date**”), which written notification shall be delivered to the Participant no later than 15 Business Days prior to the Additional Payment Date.

## 2.3 **[Maximum Adjusted Cost Per Dose**

Gavi shall not allocate the Participant doses of Approved Vaccine if the Adjusted Cost per Dose for a particular Approved Vaccine is greater than the Maximum Adjusted Cost Per Dose.]<sup>6</sup>

# 3. **PAYMENT**

## 3.1 **Payments to Gavi**

- (a) Any payments due from the Participant to Gavi under this Agreement, shall be made to the COVAX Facility Account for value on such date by 12 noon.
- (b) The Participant's obligation to make payments due to a procurement agent or the Specified Manufacturer shall not be deemed to have been satisfied for the purposes of this Agreement until the Participant has provided Gavi with a Commitment Satisfaction Certificate in accordance with Clause 4.1(d).
- (c) The Participant shall notify Gavi in writing of any payment made pursuant to this Agreement from time to time (including any payment made to a procurement agent or the Specified Manufacturer).
- (d) All payments made pursuant to this Agreement shall be in USD.

## 3.2 **Business Days**

Any payment which is due to be made on a day that is not a Business Day shall be made on the next Business Day in the same calendar month (if there is one) or the preceding Business Day (if there is not).

## 3.3 **Enforcement Rights**

If the Participant does not make:

- (i) the Down Payment on the Participant Payment Deadline; or
- (ii) having in its discretion agreed to make an Additional Payment, an Additional Payment on the Additional Payment Date; or
- (iii) the payment of the Adjusted Cost Per Dose as determined and in accordance with Clause 2.1(ii) above,

then Gavi shall be entitled to pursue all rights available to it under this Agreement including under Clause 4.3 and 8.1.

---

<sup>6</sup> Note: to be included if the Participant is not willing to receive an Approved Vaccine above a price that is double the All-Inclusive Weighted Average Estimated Cost Per Dose (i.e. US\$21.10).

### 3.4 **No set-off by Participant**

All payments to be made by the Participant under this Agreement shall be calculated and be made without (and free and clear of any deduction for) withholding, set-off or counterclaim.

## 4. **PROCUREMENT**

### 4.1 **Participant Doses**

- (a) Gavi shall notify the Participant in writing of its Participant Doses from time to time and such notifications shall be binding on the Parties and constitute conclusive evidence of the Participant Doses.
- (b) The Participant undertakes:
  - (i) to purchase its Participant Doses from the Specified Manufacturer (paying the amounts to the procurement agent, Specified Manufacturer and/or Gavi as notified to the Participant in accordance with Clause 2.1(ii)) as soon as the doses become available and in any event within such period as Gavi shall notify the Participant from time to time (the “**Procurement Period**”); and
  - (ii) not to negotiate the cost per dose with the Specified Manufacturer.
- (c) The Participant acknowledges and agrees that:
  - (i) all doses will be allocated in accordance with the Terms and Conditions and the Allocation Framework;
  - (ii) the aggregate cost per dose of its Participant Doses will be at the Adjusted Cost Per Dose; and
  - (iii) Gavi shall notify the Participant in writing of its Remaining Participant Doses from time to time and such notifications shall be binding on the Parties and constitute conclusive evidence of the Remaining Participant Doses.
- (d) The Participant shall provide a certificate of confirmation to Gavi within 10 Business Days after it has satisfied its obligation to purchase the Participant Doses. The certificate of confirmation shall be in the form set out in Schedule 2 (*Commitment Satisfaction Certificate*) and shall be countersigned by the Specified Manufacturer and/or a procurement agent (the “**Commitment Satisfaction Certificate**”). The Commitment Satisfaction Certificate shall be deemed to be confirmation that any amounts to be paid by the Participant to the Specified Manufacturer and/or a procurement agent have been duly received.

### 4.2 **Additional Doses**

- (a) The Participant may make a request to Gavi to purchase additional doses of the Approved Vaccine in accordance with Clause 4.2(c).
- (b) The allocation and subsequent purchase of additional doses of Approved Vaccine shall be made in accordance with the Terms and Conditions.
- (c) For the avoidance of doubt the Participant shall have no claim against Gavi if no additional doses of Approved Vaccine are available.



#### 4.3 **Failure to procure its Participant Doses**

Without prejudice to the indemnity in Clause 8, if the Participant does not purchase its Participant Doses (or part thereof) for any reason or exchange its Participant Doses on the COVAX Exchange, the Participant shall notify Gavi immediately and will be obliged to pay Gavi the cost of its Remaining Participant Doses (as notified to the Participant in accordance with Clause 4.1(c)(iii)), which shall be an amount equal to the product of the Adjusted Cost Per Dose and the Remaining Participant Doses.

### 5. **FINANCING CONDITION**

- (a) The Participant undertakes that it shall use all reasonable endeavours to procure a guarantee or other form of credit support for the Financial Guarantee Amount, and any Additional Payments, that is on demand, irrevocable, unconditional and in form and substance satisfactory to Gavi acting in its sole discretion, by no later than 5pm Geneva time on the Financial Guarantee Deadline (or such later date as may be agreed with Gavi, acting in its sole discretion, in writing).
- (b) The procurement by the Participant of the guarantee or other credit support pursuant to paragraph (a) above shall constitute satisfaction of the “**Financing Condition**” under this Agreement.
- (c) If the Participant fails to satisfy the Financing Condition by 5pm Geneva time on the Financial Guarantee Deadline (or such later date as may be agreed with Gavi, acting in its sole discretion, in writing), Gavi may by notice in writing terminate this Agreement pursuant to Clause 11(a).

### 6. **ASSIGNMENT**

#### 6.1 **Assignment by Gavi**

Gavi may transfer to any agency that Gavi deems appropriate (acting in its sole discretion) (the “**Gavi Transferee**”) by way of absolute assignment or transfer in or substantially in the form set out in Part A, Schedule 3 (*Form of Assignment Agreement*), all of its rights, title, benefit, interest and/or obligations hereunder, including with respect to the payment obligations of the Participant hereunder. Gavi shall give notice, in or substantially in the form set out in Part B of Schedule 3 (*Form of Notice of Assignment*) to the Participant of such assignment or transfer. The Participant shall acknowledge in writing, addressed to Gavi and the Gavi Transferee, its receipt of notice of any such transfer or assignment. Upon such transfer or assignment to the Gavi Transferee, all references to Gavi in this Agreement shall be deemed to mean the Gavi Transferee, and the rights, title, benefit, interest and/or obligations hereunder (including with respect to the payment obligations of the Participant hereunder) transferred or assigned to the Gavi Transferee shall not be capable of being further transferred, assigned or otherwise disposed of in any manner whatsoever (whether absolutely or by way of security) without the prior written consent of the Participant.

#### 6.2 **Assignment by the Participant**

Other than a transfer through the COVAX Exchange, the Participant may only transfer all but not part of its rights, title, interest and obligations hereunder to any appropriate ministry or government agency of that same Participant of the same or higher credit standing provided that such transfer is notified in writing in advance to Gavi.

## **7. TAX GROSS UP AND INDEMNITIES**

### **7.1 Definitions**

(a) In this Agreement:

“**Tax Credit**” means a credit against, relief or remission for, or repayment of any Tax.

“**Tax Deduction**” means a deduction or withholding for or on account of Tax from a payment under this Agreement.

“**Tax Payment**” means either the increase in a payment made by the Participant to Gavi under Clause 7.2 or a payment under Clause 7.3.

- (b) Unless a contrary indication appears, in this Clause 7 a reference to "determines" or "determined" means a reasonable determination of the party making the determination, supported by evidence provided to the other party.

### **7.2 Tax gross-up**

- (a) The Participant shall make all payments to be made by it without any Tax Deduction.
- (b) The Participant shall promptly upon becoming aware that it must make a Tax Deduction (or that there is any change in the rate or the basis of a Tax Deduction) notify Gavi accordingly. Similarly, Gavi shall notify the Participant on becoming so aware in respect of a payment payable to it.
- (c) If a Tax Deduction is required by law to be made by the Participant, the amount of the payment due from the Participant shall be increased to an amount which (after making any Tax Deduction) leaves an amount equal to the payment which would have been due if no Tax Deduction had been required.
- (d) If a Participant is required to make a Tax Deduction, that Participant shall make that Tax Deduction and any payment required in connection with that Tax Deduction within the time allowed and in the minimum amount required by law.
- (e) Within 30 days of making either a Tax Deduction or any payment required in connection with that Tax Deduction, the Participant making that Tax Deduction shall deliver to Gavi a statement under Section 975 of the UK Income Tax Act 2007 or other evidence satisfactory to Gavi, acting reasonably, that the Tax Deduction has been made or (as applicable) as soon as is practically possible, evidence that the required payment has been paid to the relevant taxing authority.

### **7.3 Tax indemnity**

- (a) The Participant shall (within 40 days of demand by Gavi) pay to Gavi an amount equal to the loss, liability or cost which Gavi determines (supported by evidence which Gavi shall provide to the Participant) will be or has been (directly or indirectly) suffered for or on account of Tax by Gavi in respect of this Agreement. The indemnity given by the Participant under this Clause 7.3(a) shall extend to any VAT or sales tax which is or may become chargeable on any supply made by Gavi to the Participant in connection with this Agreement.
- (b) Paragraph 7.3(a) above shall not apply:
- (i) with respect to any Tax assessed on Gavi:

(A) under the law of the jurisdiction in which Gavi is incorporated or, if

different, the jurisdiction (or jurisdictions) in which Gavi is treated as resident for tax purposes; or

- (B) under the law of the jurisdiction in which Gavi's head office is located in respect of amounts received or receivable in that jurisdiction,

if that Tax is imposed on or calculated by reference to the net income received or receivable (but not any sum deemed to be received or receivable) by Gavi; or

- (ii) to the extent a loss, liability or cost is compensated for by an increased payment under Clause 7.2.

#### **7.4 Tax Credit**

If the Participant makes a Tax Payment and Gavi determines that:

- (i) a Tax Credit is attributable either to an increased payment of which that Tax Payment forms part, or to that Tax Payment or to a Tax Deduction in consequence of which that Tax Payment was required; and
- (ii) Gavi has obtained, utilised and retained that Tax Credit,

Gavi shall pay an amount to the Participant which Gavi determines will leave it (after that payment) in the same after-Tax position as it would have been in had the Tax Payment not been required to be made by the Participant.

#### **7.5 Mitigation by Gavi**

Gavi shall, in consultation with the Participant, take all reasonable steps (including completing relevant forms and claiming relevant reliefs and tax credits) to mitigate any circumstances which arise and which would result in any amount becoming payable under or pursuant to Clause 7.2 or Clause 7.3. This Clause does not limit the obligations of the Participant under this Agreement, and Gavi shall not be obliged to take any action which it considers (acting reasonably) is prejudicial to it. The Participant shall indemnify Gavi against any reasonable cost or expense incurred by Gavi in taking any such action.

### **8. INDEMNITIES**

#### **8.1 General indemnities**

The Participant shall promptly indemnify Gavi against any cost, loss or liability incurred by Gavi (and supported by evidence which Gavi shall provide to the Participant) as a result of failure, or delay, by the Participant to: (i) pay any sum due from it under this Agreement; or (ii) otherwise comply with any of its other obligations under Clauses 2 (*Commitment to Pay and Procure*), 3 (*Payments*), 4 (*Procurement*), 5 (*Financing Condition*) and 7 (*Tax Gross up and Indemnities*) of this Agreement.

#### **8.2 Separate indemnities**

Each indemnity obligation arising under this Agreement shall:

- (i) constitute a separate and independent obligation from the other obligations in this Agreement;
- (ii) give rise to a separate and independent cause of action;

- (iii) apply irrespective of any indulgence granted by Gavi or any other person; and
- (iv) continue in full force and effect despite any judgment, order, claim or proof for a liquidated amount in respect of any sum due under this Agreement or any other judgment or order.

### 8.3 Mitigation by Gavi

Gavi shall, in consultation with the Participant, take all reasonable steps to mitigate any circumstances which arise and which would result pursuant to Clause 8.1, including using reasonable endeavours to re-allocate Participant Doses which have not been purchased to other Participants. This Clause does not limit the obligations of the Participant under this Agreement, and Gavi shall not be obliged to take any action which it considers (acting reasonably) is prejudicial to it. The Participant shall indemnify Gavi against any reasonable cost or expense incurred by Gavi in taking any such action.

## 9. UNDERTAKINGS OF THE PARTICIPANT

- (a) The undertakings in this Clause 9 shall remain in force from the date of this Agreement for so long as any obligation hereunder remains outstanding.
- (b) The Participant shall promptly obtain, comply with and do all that is necessary to maintain in full force and effect any Authorisation required under any law or regulation to enable it to perform its obligations under this Agreement.
- (c) The Participant represents and warrants to Gavi that:
  - (i) it has full power and authority to enter into, perform and deliver this Agreement and the transactions contemplated herein;
  - (ii) this Agreement has been duly authorised, executed and delivered by it and constitutes valid and legally binding obligations of it and enforceable against it in accordance with its terms;
  - (iii) all actions required to be taken (including the obtaining of any Authorisation) for the entry by it into this Agreement, the carrying out of the other transactions contemplated herein, or the compliance by it with the terms hereof, as the case may be, have been taken and any Authorisations are in full force and effect;
  - (iv) its execution and delivery of this Agreement, the consummation of the transactions herein contemplated and compliance with the terms hereof do not: (a) conflict with or result in a breach of any of the terms or provisions of, or constitute a default under, any indenture, trust deed, mortgage or other agreement or instrument to which it is a party or by which it or any of its properties is bound; or (b) infringe any existing applicable law, rule, regulation judgment, order or decree applicable to it or any international treaty convention or agreement to which it is a part or by which it is bound; and
  - (v) under the laws of the Participant it is not necessary that any stamp, registration or similar tax be paid on or in relation to this Agreement or the transactions contemplated by this Agreement.

- (d) The Participant shall promptly notify Gavi in writing immediately on becoming aware of any breach of the representations and warranties given in Clause 9(c).

#### 10. **TERM**

This Agreement commences on the date hereof and, unless terminated pursuant to Clause 11 (*Termination*), shall end on

- (i) if there is no Approved Vaccine prior to the third anniversary of the date of this Agreement, the third anniversary of the date of this Agreement;
- (ii) if there is an Approved Vaccine prior to the third anniversary of the date of this Agreement, the date on which the Participant has delivered its Commitment Satisfaction Certificate to Gavi or, if applicable, met any further commitments to procure additional doses pursuant to Clause 4; or
- (iii) the date on which Gavi and the Participant mutually agree in writing to terminate this Agreement.

#### 11. **TERMINATION**

- (a) Gavi may terminate this Agreement if the Participant is in breach of Clause 2, fails to satisfy the Financing Condition or commits a material breach of any other provisions of this Agreement and fails to remedy such breach within 15 Business Days (or such longer period as Gavi may agree, acting in its sole discretion) of written notice of such breach by Gavi to the Participant; and
- (b) The Participant may terminate this Agreement if Gavi ceases its operations or is in material breach of this Agreement and fails to remedy such breach within 15 Business Days (or such longer period as the Participant may agree, acting in its sole discretion) of written notice from the Participant to Gavi.

#### 12. **TERMS AND CONDITIONS**

Subject to Clause 1.6, the Parties agree that the following paragraphs of the Terms and Conditions shall be binding on the Participant and Gavi and enforceable against each other:

- (i) paragraph [5] (*Role of Gavi as administrator of the COVAX Facility*);
- (ii) paragraph [6] (*Non-Financial Considerations of all Participants*);
- (iii) paragraph [7] (*Liability and Indemnity*);
- (iv) paragraph [8] (*Participant Cost Structure*);
- (v) paragraph [9] (*Commitments of the Participants subscribed to the Committed Purchase Arrangement*);
- (vi) paragraph [11] (*Engagement with manufacturers*);
- (vii) paragraph [13] (*Product Choice*);
- (viii) paragraph [14] (*Vaccine allocation*);
- (ix) paragraph [15] (*Trading of Approved Vaccines / Proposed COVAX Exchange*);

- (x) paragraph [18] (*Governance, Information and Reporting*);
- (xi) paragraph [19] (*Advisory Bodies*);
- (xii) paragraph [20] (*Costs of administering the Facility*);
- (xiii) paragraph [22] (*Sign-up period*);
- (xiv) paragraph [23] (*Duration*);
- (xv) paragraph [24] (*Events of termination*); and
- (xvi) paragraph [25] (*Return of any surplus funds*).

### 13. **COMMUNICATIONS**

#### 13.1 **Methods of Communication**

- (a) Any communication under this Agreement (a “**Notice**”) shall be in writing, in English and shall either (a) be delivered in person or by courier or (b) sent by e-mail, in each case addressed to the relevant party for the attention of the appropriate person identified below.
- (b) A Notice to Gavi shall be sent to such party at the following address or to such other person and address as Gavi may notify by Notice to the Participant from time to time:

The Gavi Alliance  
 [2 Chemin des Mines,  
 Geneva CH-1202,  
 Switzerland]  
 Email: [●]  
 Attention: [●]

- (c) A Notice to the Participant shall be sent to such party at the following address or to such other person and address as the Participant may notify by Notice to Gavi from time to time:

[Participant]  
 [Address]  
 Email: [●]  
 Attention: [●]

#### 13.2 **Deemed Receipt**

The date on which any communication under this Agreement shall be deemed effective is as follows:

- (i) if delivered in person or by courier, on the date it is delivered;
- (ii) if sent by e-mail, at the time of sending, provided that no delivery failure notification is received by the sender within 24 hours of sending such communication,

provided that any communication which is received (or deemed to take effect in accordance with the foregoing) outside business hours or on a non-business day in the place of receipt shall be

deemed to take effect at the opening of business on the next following business day in such place. Any communication delivered to any party under this Agreement which is to be sent by e-mail will be written legal evidence.

#### **14. MISCELLANEOUS**

##### **14.1 Counterparts**

This Agreement may be executed in any number of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy of this Agreement.

##### **14.2 Partial invalidity**

If, at any time, any provision of this Agreement is or becomes illegal, invalid or unenforceable in any respect under any law of any jurisdiction, neither the legality, validity or enforceability of the remaining provisions nor the legality, validity or enforceability of such provision under the law of any other jurisdiction will in any way be affected or impaired.

##### **14.3 Remedies and waivers**

No failure to exercise, nor any delay in exercising, on the part of Gavi, any right or remedy under this Agreement shall operate as a waiver, nor shall any single or partial exercise of any right or remedy prevent any further or other exercise or the exercise of any other right or remedy. The rights and remedies provided in this Agreement are cumulative and not exclusive of any rights or remedies provided by law.

##### **14.4 Amendments and waivers**

No term of this Agreement may be amended or waived without the prior written consent of Gavi and the Participant.

#### **15. GOVERNING LAW**

The terms of this Agreement shall be interpreted and applied in accordance with their true meaning and intended effect independently of any system of national law, whether federal or state law. If the arbitral tribunal finds the terms of this Agreement to be ambiguous or unclear, then in those circumstances only, the arbitral tribunal may refer to and apply English law as it deems appropriate.

#### **16. DISPUTE RESOLUTION**

Any dispute, controversy or claim (“**Dispute**”) between the Parties arising out of or in connection with this Agreement shall be submitted to arbitration at the request of either Party. The arbitration shall be conducted in accordance with the then-current rules of the United Nations Commission of International Trade Law (UNCITRAL). Gavi and the Participant shall each appoint one arbitrator, and the two arbitrators so appointed shall jointly appoint a third arbitrator who shall be the chairperson. If either Party fails to appoint an arbitrator, the appointing authority shall instead be the President of the Swiss Arbitration Association. The arbitration proceedings shall take place in Geneva (which is the seat of the arbitration) and shall be conducted in English. The Parties agree to be bound by any arbitration award, as the final adjudication of any Dispute.

**SCHEDULE 1**  
**TERMS AND CONDITIONS**



**SCHEDULE 2**  
**COMMITMENT SATISFACTION CERTIFICATE**

**SCHEDULE 3**  
**PART A**  
**FORM OF ASSIGNMENT AGREEMENT**  
**[TO BE INSERTED]**

**SCHEDULE 3**  
**PART B**  
**FORM OF NOTICE OF ASSIGNMENT**  
**[TO BE INSERTED]**

## The Participant

EXECUTED by

\_\_\_\_\_

in the presence of:

}

Witness' Signature: \_\_\_\_\_

Name:

Occupation:

Address:

Gavi

EXECUTED

by **THE GAVI ALLIANCE**,

acting by its duly authorised attorney

in the presence of:

}

Witness' Signature: \_\_\_\_\_

Name:

Occupation:

Address: